Literature DB >> 25805524

Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature.

Sanjiv M Baxi1,2, Dominic Chan3, Vivek Jain4.   

Abstract

We report a case of clearance of persistent bacteremia due to daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus native mitral valve endocarditis with a combination of ceftaroline and daptomycin, in an 81-year-old medically complex patient who was not an operative candidate.

Entities:  

Keywords:  Antimicrobial resistance; Bacteremia; Ceftaroline; Endocarditis; Staphylococcus aureus

Mesh：

Substances：

Year:  2015        PMID： 25805524      PMCID： PMC4583316          DOI： 10.1007/s15010-015-0763-0

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  22 in total

1.  Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin.

Authors:  Luis A Marcos; Bernard C Camins
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

2.  In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates.

Authors:  Louis D Saravolatz; Joan Pawlak; Leonard B Johnson
Journal:  Clin Infect Dis       Date:  2012-05-21       Impact factor: 9.079

3.  Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sensititre System and the MicroScan System. Comparison with results from the conventional Etest and CLSI standardized MIC methods.

Authors:  Rohan Nadarajah; Linda R Post; Catherine Liu; Steven A Miller; Daniel F Sahm; Geo F Brooks
Journal:  Am J Clin Pathol       Date:  2010-06       Impact factor: 2.493

4.  Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding.

Authors:  Abhay Dhand; Arnold S Bayer; Joseph Pogliano; Soo-Jin Yang; Michael Bolaris; Victor Nizet; Guiquing Wang; George Sakoulas
Journal:  Clin Infect Dis       Date:  2011-07-15       Impact factor: 9.079

5.  Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report.

Authors:  Karissa Jongsma; Jeremiah Joson; Arash Heidari
Journal:  J Antimicrob Chemother       Date:  2013-01-22       Impact factor: 5.790

6.  Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.

Authors:  Nasir M Ahmad; Albert D Rojtman
Journal:  Ann Pharmacother       Date:  2010-03-30       Impact factor: 3.154

Review 7.  Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature.

Authors:  S J van Hal; D L Paterson; I B Gosbell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-30       Impact factor: 3.267

8.  Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus.

Authors:  Helio S Sader; Paul R Rhomberg; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

9.  Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  Ryan Yu; Suzanne E Dale; Deborah Yamamura; Vida Stankus; Christine Lee
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

10.  Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains.

Authors:  Katie E Barber; Cortney E Ireland; Natalia Bukavyn; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2014-01-18
View more
  7 in total

Review 1.  Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections.

Authors:  Kyle C Molina; Vanthida Huang
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

Review 2.  The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Authors:  Kyle C Molina; Taylor Morrisette; Matthew A Miller; Vanthida Huang; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Nicolas Cortes-Penfield; Nora T Oliver; Andrew Hunter; Maria Rodriguez-Barradas
Journal:  Infect Dis (Lond)       Date:  2018-03-06

4.  Daptomycin-β-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis.

Authors:  Henry F Chambers; Li Basuino; Stephanie M Hamilton; Eun Ju Choo; Pamela Moise
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 5.  Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review.

Authors:  Reese A Cosimi; Nahal Beik; David W Kubiak; Jennifer A Johnson
Journal:  Open Forum Infect Dis       Date:  2017-05-02       Impact factor: 3.835

6.  Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Majid Taati Moghadam; Alex van Belkum; Somayeh Yaslianifard; Davood Darban-Sarokhalil
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

7.  Combination of ceftaroline and daptomycin as treatment for complicated osteomyelitis.

Authors:  Ana Gascón; Marta Castresana; Natalia Alzueta; Marta Marin; María Pío; Aitziber Echeverria
Journal:  Eur J Hosp Pharm       Date:  2020-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.